ReviewExpert opinion on pharmacotherapy2013
Kidney stones: an update on current pharmacological management and future directions.
Review in Expert opinion on pharmacotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis.Journal of nephrology · 2016Pooled it
- Trial
- A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC).Kidney360 · 2020Trial
- Development and validation of a predictive model for calcium oxalate kidney stone recurrence integrating gut microbiome and clinical features.World journal of urology · 2026Article
- Allicin inhibits kidney stone formation by suppressing the TNF/NF-κB pathway: Experimental validation through network pharmacology, in vitro, and in vivo studies.Molecular biology reports · 2026Article
- Association between triglyceride levels and upper urinary tract calcium stones recurrence.BMC nephrology · 2026Article
- Nephrolithiasis associated with sulfadiazine therapy in an infant with congenital toxoplasmosis: a case report.BMC pediatrics · 2026Article
- Pediatric hyperuricemia: genetic basis, metabolic mechanisms, and clinical implications.Frontiers in endocrinology · 2026Review
- Analysis of toxicity and mechanisms of aspartame in kidney stones with network toxicology and molecular docking strategy.Scientific reports · 2025Article
- A Fresh Look at Oral Chemolysis for Non-Symptomatic Kidney Stones-Comparative Research of Potassium Citrate and Allopurinol Combination-Is Treatment Possible Without Stone Analysis?Journal of clinical medicine · 2025Article
- Linoleic Acid Enhances Renal Tubular Epithelial Cells Autophagy Caused by Calcium Oxalate Monohydrate Crystals.Journal of cellular and molecular medicine · 2024Article
- Low daily water intake profile-is it a contributor to disease?Nutrition and health · 2024Review
- Urolithiasis: From pathogenesis to management (part two).Asian journal of urology · 2024Article
- A critical appraisal of urolithiasis clinical practice guidelines using the AGREE II instrument.Translational andrology and urology · 2023Article
- Hormonal and molecular characterization of calcium oxalate stone formers predicting occurrence and recurrence.Urolithiasis · 2023Article
- Anti-urolithiatic activity ofJournal of traditional and complementary medicine · 2021Article
- Article
- Sex differences in redox homeostasis in renal disease.Redox biology · 2020Review
- Pathological Mineralization: The Potential of Mineralomics.Materials (Basel, Switzerland) · 2019Review
- Twenty-four-hour urine osmolality should be used in combination with other urine parameters in urolithiasis patients.International urology and nephrology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionKidney stones are a common problem worldwide with substantial morbidities and economic costs. Medical therapy reduces stone recurrence significantly. Much progress has been made in the last several decades in improving therapy of stone disease. AREAS COVERED: This review discusses i) the effect of medical expulsive therapy on spontaneous stone passage, ii) pharmacotherapy in the prevention of stone recurrence and iii) future directions in the treatment of kidney stone disease. EXPERT OPINION: Fluid intake to promote urine volume of at least 2.5 L each day is essential to prevent stone formation. Dietary recommendations should be adjusted based on individual metabolic abnormalities. Properly dosed thiazide treatment is the standard therapy for calcium stone formers with idiopathic hypercalciuria. Potassium alkali therapy is considered for hypocitraturia, but caution should be taken to prevent potential risk of calcium phosphate stone formation. For absorptive hyperoxaluria, low oxalate diet and increased dietary calcium intake are recommended. Pyridoxine has been shown effective in some cases of primary hyperoxaluria type I. Allopurinol is used in calcium oxalate stone formers with hyperuricosuria. Treatment of cystine stones remains challenging. Tiopronin can be used if urinary alkalinization and adequate fluid intake are insufficient. For struvite stones, complete surgical removal coupled with appropriate antibiotic therapy is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.